journal
Evidence pageCAR T cell viability release testing and clinical outcomes: is there a lower limit?
Blood (Chong EA et al.), 134(21):1873–1875
Published Sep 25, 2019accessed Sep 18, 2026Updated Sep 19, 2026
Original source
https://pmc.ncbi.nlm.nih.gov/articles/PMC6872962/
pmc.ncbi.nlm.nih.gov
Verification
| Verification | Not yet verified |
| Evidence level | — |
| Source | journal |
| Link status | Reachable at last check |
Official claims are statements by the provider; they are not verified by worldwiki unless marked otherwise. Source policy
Cited by (8)
FactCell Viability: CAR T (CTL019) viability release specification = At least 80% for the commercial product; early clinical trials used at least 70% %FactCell Viability: Viability and clinical outcome (CAR T) = No link was found between product viability below 80% and response, expansion or survival in 123 pediatric ALL and 25 adult DLBCL patientsAnswerHow is cell viability percentage calculated?AnswerWhat is an acceptable cell viability for cell therapy products?AnswerTrypan blue vs MTT: which cell viability assay should I use?AnswerWhy does cell viability drop after thawing cryopreserved cells?AnswerDoes higher cell viability mean better fat graft survival?ArticleCell Viability: Definition, Assays, Acceptance Criteria and Limits of Interpretation